ERLANGER MEDICAL CENTER
- Type
- Teaching hospital
- Where
- CHATTANOOGA, TN
- Medicare CCN
- 440104
- Received
- $761,438 in 274 records, 2020 ($204,164 general, $557,273 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ERLANGER MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: ERLANGER MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 46 | $204,164 |
| 2020 | Research payment | 228 | $557,273 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 228 | $557,273 |
| Education | 15 | $83,262 |
| Grant | 6 | $68,564 |
| Space rental or facility fees (teaching hospital only) | 21 | $48,905 |
| Charitable Contribution | 1 | $2,000 |
| Gift | 3 | $1,431 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Intuitive Surgical, Inc. | $14,880 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $3,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-23 | SEAGEN INC. | $2,000 | Research payment | Cash or cash equivalent | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | 2020 | |
| 2020-12-10 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Arrhythmias and Heart Failure | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2020 |
| 2020-12-10 | Ipsen Biopharmaceuticals, Inc | $250 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $247 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $59 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $59 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-07 | Medical Device Business Services, Inc. | $487 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-12-03 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-11-26 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-11-17 | F. Hoffmann-La Roche AG | $8,662 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2020 |
| 2020-11-17 | Intuitive Surgical, Inc. | $1,100 | Gift | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $7,500 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-11-04 | Abbott Laboratories | $780 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-10-26 | Medical Device Business Services, Inc. | $974 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-10-23 | Ipsen Biopharmaceuticals, Inc | $1,822 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt | 2020 |
| 2020-10-20 | SEAGEN INC. | $19,525 | Research payment | Cash or cash equivalent | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | 2020 | |
| 2020-10-15 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-10-07 | Arthrex, Inc. | $15,000 | Research payment | Cash or cash equivalent | DISTAL EXTREMITIES INSTRUMENTS FOOT & ANKLE MIDFOOT INSTRUMENTS Device, DISTAL EXTREMITIES | Anatomical Complications and Risks of Plantar Plating for Lapidus Fusions | 2020 |
| 2020-10-07 | Merck Sharp & Dohme LLC | $750 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $1,105 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-10-01 | Merck Sharp & Dohme LLC | $2,075 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-09-30 | Intuitive Surgical, Inc. | $14,880 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-30 | Intuitive Surgical, Inc. | $3,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-30 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-09-24 | Synthes GmbH | $6,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-09-11 | Medical Device Business Services, Inc. | $939 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-09-09 | Genentech, Inc. | $29,564 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-09-09 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $271 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-02 | SEAGEN INC. | $2,500 | Research payment | Cash or cash equivalent | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | 2020 | |
| 2020-08-27 | Abbott Laboratories | $6,020 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-08-21 | Merck Sharp & Dohme LLC | $5,815 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-08-19 | Arthrex, Inc. | $10,000 | Research payment | Cash or cash equivalent | Clinical Outcome of Midfoot Arthrodesis Using the Arthrex DynaNite Staple | 2020 | |
| 2020-08-19 | Abbott Laboratories | $487 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-08-12 | Arthrex, Inc. | $30,000 | Research payment | Cash or cash equivalent | Minimally Invasive Akin Osteotomy Fixated with a 2.5mm Fully Threaded Compression Screw | 2020 | |
| 2020-08-12 | Concordance Healthcare Solutions, LLC | $2,000 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-08-12 | Abbott Laboratories | $810 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Arrhythmias and Heart Failure | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2020 |
| 2020-08-06 | Novocure Inc. | $450 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and | 2020 |
| 2020-08-05 | Abbott Laboratories | $780 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-08-04 | SEAGEN INC. | $1,750 | Research payment | Cash or cash equivalent | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | 2020 | |
| 2020-08-03 | Synthes GmbH | $30,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-03 | Medical Device Business Services, Inc. | $3,692 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-07-29 | Abbott Laboratories | $2,063 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-07-29 | CSL Behring | $21 | Education | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | 2020 | |
| 2020-07-29 | CSL Behring | $17 | Education | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | 2020 | |
| 2020-07-29 | CSL Behring | $11 | Education | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | 2020 | |
| 2020-07-27 | PFIZER INC. | $8,375 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-07-24 | Merck Sharp & Dohme LLC | $5,404 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-07-23 | Ipsen Biopharmaceuticals, Inc | $2,733 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt | 2020 |
| 2020-07-22 | Boston Scientific Corporation | $597 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | MADIT S ICD | 2020 |
| 2020-07-20 | Boston Scientific Corporation | $2,460 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-07-20 | Gilead Sciences, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-07-16 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-07-14 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-14 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-30 | Intuitive Surgical, Inc. | $14,880 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-06-30 | Intuitive Surgical, Inc. | $3,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-06-30 | Intuitive Surgical, Inc. | $2,062 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-06-24 | Genentech, Inc. | $6,483 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-06-22 | Boston Scientific Corporation | $9,585 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-06-09 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-06-05 | Linvatec Corporation | $2,555 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-06-01 | Merck Sharp & Dohme LLC | $2,075 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-05-28 | Medical Device Business Services, Inc. | $3,164 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-05-13 | Abbott Laboratories | $2,717 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-05-13 | Abbott Laboratories | $1,593 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Arrhythmias and Heart Failure | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2020 |
| 2020-05-12 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $247 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $148 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-12 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-05-08 | Merck Sharp & Dohme LLC | $5,979 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-05-07 | Ipsen Biopharmaceuticals, Inc | $1,822 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport abobotulinu | 2020 |
| 2020-05-04 | Medical Device Business Services, Inc. | $452 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-05-01 | Genentech, Inc. | $6,796 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-05-01 | F. Hoffmann-La Roche AG | $408 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2020 |
| 2020-04-29 | Abbott Laboratories | $4,153 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-04-29 | Boston Scientific Corporation | $324 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | MADIT S ICD | 2020 |
| 2020-04-27 | Merck Sharp & Dohme LLC | $1,664 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-04-27 | Merck Sharp & Dohme LLC | $1,664 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-04-24 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-04-22 | Abbott Laboratories | $6,337 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-04-21 | Boston Scientific Corporation | $8,795 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-04-14 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $331 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $247 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $247 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-04-08 | Abbott Laboratories | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Omnilink Elite vascular stent system Device, Vascular | 2020 | |
| 2020-04-06 | Medical Device Business Services, Inc. | $19,392 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-04-06 | E.R. Squibb & Sons, L.L.C. | $144 | Research payment | Cash or cash equivalent | Ph III MIBC Nivo NKTR vs Nivo mono | 2020 | |
| 2020-03-31 | Intuitive Surgical, Inc. | $14,880 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-03-31 | Intuitive Surgical, Inc. | $3,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-03-31 | BIOTRONIK INC. | $1,275 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | QP ExCELs | 2020 |
| 2020-03-31 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-03-27 | Bard Peripheral Vascular, Inc. | $950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-03-26 | CSL Behring | $825 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-26 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-03-25 | Abbott Laboratories | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Endurity Pacemaker Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-03-25 | Abbott Laboratories | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Ensite Cardiac Mapping System Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-03-23 | Merck Sharp & Dohme LLC | $3,739 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-03-23 | E.R. Squibb & Sons, L.L.C. | $2,450 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB NMI Bladder BCG Unresponsive Nivo or Nivo IDO | 2020 |
| 2020-03-17 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2020 |
| 2020-03-13 | Penumbra, Inc. | $2,589 | Education | Cash or cash equivalent | 2020 | ||
| 2020-03-12 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-03-10 | Eli Lilly and Company | $25,747 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-03-09 | Merck Sharp & Dohme LLC | $105 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $77 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $49 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-09 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2020 |
| 2020-03-05 | Abbott Laboratories | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Allure CRT Pacemaker Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-03-02 | E.R. Squibb & Sons, L.L.C. | $36,879 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III 1L GBM Methylated nivo mono chemo RT | 2020 |
| 2020-03-02 | Genentech, Inc. | $23,279 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-03-02 | Boston Scientific Corporation | $1,325 | Research payment | Cash or cash equivalent | RESONATE Device, TACHY | PREEMPT HF | 2020 |
| 2020-03-02 | Merck Sharp & Dohme LLC | $302 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-03-02 | Merck Sharp & Dohme LLC | $302 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-02-27 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | Confirm Rx Device, Cardiac Arrhythmias and Heart Failure | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2020 |
| 2020-02-26 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,009 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2020 | |
| 2020-02-26 | Abbott Laboratories | $950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiac Mapping System Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-02-25 | Genentech, Inc. | $17,694 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-02-25 | Novocure Inc. | $1,000 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2020 |
| 2020-02-25 | F. Hoffmann-La Roche AG | $954 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2020 |
| 2020-02-25 | Novocure Inc. | $600 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and | 2020 |
| 2020-02-24 | Merck Sharp & Dohme LLC | $5,404 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 plus Epacadostat vs Sta | 2020 |
| 2020-02-21 | Amarin Pharma, Inc. | $1,009 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-02-21 | Medical Device Business Services, Inc. | $950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Carto Smarttouch Device, Cardiology | 2020 |
The latest 200 records of 274.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chattanooga, TN, county Hamilton County, TN, state Tennessee; placed by its city name.
| Measure | Place (city or town) Chattanooga, TN | County Hamilton County, TN | State Tennessee |
|---|---|---|---|
| Population B01003 | 185,783 | 376,192 | 7,066,383 |
| Population, 2020 census P1 | 181,099 | 366,207 | 6,910,840 |
| Median age B01002 | 36.3 | 39.5 | 38.9 |
| Under 18 B01001 | 21.0% | 21.1% | 22.2% |
| 65 and over B01001 | 17.3% | 18.4% | 17.1% |
| Households B11001 | 79,084 | 154,181 | 2,824,277 |
| Foreign born B05002 | 8.3% | 6.6% | 6.1% |
| Median household income B19013 | $64,523 | $76,183 | $69,595 |
| Median family income B19113 | $85,907 | $99,031 | $87,314 |
| Per capita income B19301 | $41,600 | $45,341 | $39,437 |
| Poverty rate B17001 | 19.1% | 13.1% | 13.8% |
| Unemployment rate B23025 | 5.4% | 4.4% | 4.7% |
| Civilian labor force B23025 | 97,199 | 195,869 | 3,527,571 |
| Mean commute (minutes) B08013 | 18.5 | 22.1 | 25.7 |
| Bachelor's degree or higher B15003 | 36.0% | 37.5% | 31.1% |
| Housing units B25001 | 87,970 | 168,013 | 3,143,670 |
| Owner-occupied B25003 | 52.4% | 63.9% | 66.9% |
| Renters B25003 | 47.6% | 36.1% | 33.1% |
| Median home value B25077 | $283,200 | $312,800 | $286,700 |
| Median gross rent B25064 | $1,256 | $1,253 | $1,189 |
| White, not Hispanic B03002 | 55.5% | 68.3% | 71.0% |
| Black B03002 | 27.6% | 16.9% | 15.4% |
| Hispanic or Latino B03002 | 10.0% | 8.0% | 7.4% |
| Asian B03002 | 2.3% | 2.1% | 1.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chattanooga, TN.
Comments